Free tool
FAERS Monitor: Cipro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019537 or its brand name (Cipro, Ciprofloxacin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
97,364
Serious
81,282
83% of reports
Hospitalization
37,918
Death reported
9,759
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity6,288
- pain6,189
- fatigue6,120
- nausea5,925
- diarrhoea5,915
- arthralgia5,639
- drug ineffective5,195
- dyspnoea4,813
- acute kidney injury4,798
- off label use4,695
- chronic kidney disease4,552
- vomiting4,503
- pyrexia4,273
- anxiety4,203
- headache4,130
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,014 |
| 2005 | 1,124 |
| 2006 | 1,306 |
| 2007 | 1,287 |
| 2008 | 1,819 |
| 2009 | 1,994 |
| 2010 | 2,250 |
| 2011 | 3,343 |
| 2012 | 3,228 |
| 2013 | 3,178 |
| 2014 | 3,522 |
| 2015 | 4,871 |
| 2016 | 6,922 |
| 2017 | 5,600 |
| 2018 | 8,113 |
| 2019 | 9,947 |
| 2020 | 7,219 |
| 2021 | 6,613 |
| 2022 | 5,320 |
| 2023 | 5,614 |
| 2024 | 5,347 |
| 2025 | 4,735 |
| 2026 | 2,989 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,956,795 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 4,552 | 13.7 | 13.3 | 50,563 |
| drug hypersensitivitySignal | 6,288 | 7.2 | 7.0 | 32,904 |
| acute kidney injurySignal | 4,798 | 7.0 | 6.8 | 23,886 |
| anxietySignal | 4,203 | 3.2 | 3.1 | 6,435 |
| arthralgiaSignal | 5,639 | 3.0 | 2.9 | 7,344 |
| pyrexiaSignal | 4,273 | 2.7 | 2.6 | 4,549 |
| painSignal | 6,189 | 2.2 | 2.1 | 4,072 |
| vomitingSignal | 4,503 | 2.1 | 2.0 | 2,555 |
| diarrhoea | 5,915 | 2.0 | 1.9 | 2,970 |
| dyspnoea | 4,813 | 1.8 | 1.8 | 1,893 |
| fatigue | 6,120 | 1.7 | 1.7 | 1,832 |
| nausea | 5,925 | 1.6 | 1.6 | 1,456 |
| headache | 4,130 | 1.4 | 1.4 | 537 |
| off label use | 4,695 | 1.2 | 1.1 | 106 |
| drug ineffective | 5,195 | 0.9 | 0.8 | 144 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.